Arcus Biosciences Announces Board Reshuffle and New Appointment
Company Announcements

Arcus Biosciences Announces Board Reshuffle and New Appointment

Arcus Biosciences Inc (RCUS) has released an update to notify the public and investors about its officers.

On January 29, 2024, Dr. Jaen and Ms. Jarrett resigned from the Board, and Johanna Mercier was subsequently appointed as a Class II director. Their resignations did not stem from any disagreements with the Company’s operations or policies. Ms. Mercier, the Chief Commercial Officer of Gilead, was appointed in accordance with the rights established by the A&R Investor Rights Agreement and will serve without compensation. The Company plans to provide her with a standard indemnification agreement.

For further insights into RCUS corporate activity, check out TipRanks’ Insiders Trading Activity page.

For a comprehensive understanding of the announcement, you can read the full document here.

Related Articles
TipRanks Auto-Generated NewsdeskArcus Biosciences Reports Q3 2024 Results
TheFlyArcus Biosciences reports Q3 EPS ($1.00), consensus ($1.06)
TheFlyArcus Biosciences announces results from Part 1 of ARC-10 trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App